- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01562990
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
A Multi-center, Phase IB/II, Open Label, Single Arm Study of Inotuzumab Ozogamicin Plus Rituximab (R-CMC544) Alternating With Gemcitabine-oxaliplatin Plus Rituximab(R-GEMOX)in Patients Aged From 18 to 80 Years With CD20 and CD22 Positive Diffuse Large B-cell Lymphoma (DLBCL) in Relapse After/Refractory to 1ST or 2ND Line Treatment, Who Are no Candidates for Autologous Transplant.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a multicenter, phase Ib/II, open-label, single arm trial evaluating the efficacy and safety of R-CMC544 alternated with R-GEMOX in patients with CD20 and CD22 positive DLBCL in relapse after/refractory to 1st or 2nd line treatment, who are no candidates for autologous transplant.
The study consists of 2 phases. In part 1 (potential dose de-escalation phase) subjects will be enrolled at a fixed dose of CMC544. In case of occurrence of dose limiting toxicity (DLT), cohorts of 3 to 6 subjects will evaluate a de-escalating dose of CMC544 in combination with set doses of rituximab, gemcitabine and oxaliplatin in order to obtain the MTD or recommended dose of CMC544 in this regimen. In part 2 (dose expansion phase) further safety and preliminary efficacy data of the proposed combination will be analyzed.
All patients will receive two 56 day induction cycles of alternating R-CMC544 (given on day 1) and R-GEMOX (given on day 29 and 43). Patients who obtain CR or PR, will then go on a consolidation of another two 56 day cycles of alternating R-CMC544 (given on day 1) and R-GEMOX (given on day 29 and 43).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bruges, Belgium, 8000
- AZ Sint Jan
-
Gent, Belgium, 9000
- University Hospital Gent
-
Yvoir, Belgium
- CHU Mont-Godinne
-
-
-
-
-
Créteil, France, 94010
- Hôpital Henri Mondor
-
Dijon, France, 21000
- CHU de Dijon
-
Lille, France, 59037
- CHRU de Lille
-
Lyon, France, 69495
- CHU Lyon - Sud
-
Nantes, France, 44093
- Chu Hotel Dieu
-
Rennes, France, 35003
- CHU Pontchaillou
-
Rouen, France, 76038
- Centre Henri Becquerel
-
Vandoeuvre les nancy, France, 54511
- CHU Brabois
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically documented CD20 and CD22 positive diffuse large B-cell lymphoma, according to WHO classification. CD20 and CD22 immunophenotyping at initial diagnosis is acceptable. If such prior documentation is not available, then the immunophenotyping at relapse must be established by fine-needle aspirate or biopsy or by circulating CD20 and CD22 positive NHL cells from peripheral blood during screening. Upon registration the pathological report confirming the diagnosis, must be available
- In first or second relapse or refractory to first and/or second line treatment. Refractory is defined as having exhibited less than or PR to a prior rituximab containing regimen or having relapsed within 6 months of the last dose of a prior rituximab containing regimen.
- Measurable disease by bidimensional transverse CT scan assessment
- Not eligible for autologous transplantation.
- Previously treated with a chemotherapy regimen containing anthracyclines and rituximab.
- Aged 18 - 80 years.
- ECOG performance status 0 to 2.
- Minimum life expectancy of 3 months.
- Signed written informed consent.
Exclusion Criteria:
- Burkitt, mantle cell and T-cell lymphomas.
- Central nervous system or meningeal involvement by the lymphoma.
- Contraindication to any drug contained in the R-GEMOX combination chemotherapy.
- Treatment with any investigational drug within 30 days before the first planned cycle of chemotherapy and during the study.
- Nitrosurea or mitomycin C administration within 6 weeks prior to study start.
- Major debulking surgery within 3 weeks of treatment.
- Any of the following lab abnormalities (unless related to the lymphoma or bone marrow infiltration):
Absolute neutrophil count (ANC) < 1.500/µL (1,5.109/L).
Platelet count < 100.000/µL (100.109/L).
Creatinin level > 150 µmol/L (1,7 mg/dL) or 1,5 - 2,0x ULN.
Total bilirubin level > 30 µmol/L (1,8 mg/dL) or 1,5x ULN.
Serum AST/SGOT or ALT/SGPT >2,5x ULN.
- Documented infection with HIV, active hepatitis B or C infection.
- Any serious active disease or co-morbid medical condition that, according to the investigator's decision, will substantially increase the risk associated with the subject's participation in the study. Prior history of malignancies other than lymphoma with the exception of non-melanoma skin tumors (basal cell or squamous cell carcinoma of the skin) or stage 0 (in situ) cervical carcinoma unless the subject has been disease-free for 5 or more years..
- LVEF less than 50% (measured by echocardiography or scintigraphy).
- Previous myocardial infarction or pulmonary hypertension within 6 months before the first dose of investigational product.
- Congestive heart failure NYHA stage III or IV
- Known chronic liver disease (eg. Cirrhosis) or suspected alcohol abuse.
- Pregnant or lactating females
- Men and women who are biologically capable of having children not willing to use an adequate method of birth control during the study and up to 18 months after the last dose of investigational product.
- Adult patient unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: R-CMC544 and R-GEMOX
Treatment with R-CMC544 and R-GEMOX
|
2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43. 2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the Recommended Dose of R-CMC544
Time Frame: Up to 16 weeks
|
Determination of recommended dose will be based on safety parameters and particularly on incidence of DLTs
|
Up to 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OVERALL RESPONSE RATE
Time Frame: Up to 32 weeks
|
Assessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 1999 and 2007).
Patient is defined as a responder if he/she has a complete response (CR) or partial response (PR) at the end of treatment.
A descriptive analysis will also be performed considering as non-responders all patients who relapsed or died during treatment phase even if they were prematurely withdrawn as responder
|
Up to 32 weeks
|
PROGRESSION-FREE SURVIVAL
Time Frame: Up to 3.5 years
|
Progression-Free Survival will be measured from the date of inclusion to the date of first documented disease progression, relapse or death from any cause.
Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date.
|
Up to 3.5 years
|
EVENT FREE SURVIVAL
Time Frame: Up to 3.5 years
|
Event-Free Survival will be measured from the date of inclusion to the date of first documented disease progression, relapse, initiation of new anti-lymphoma therapy or death from any cause.
Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date.
|
Up to 3.5 years
|
OVERALL SURVIVAL
Time Frame: Up to 3.5 years
|
Overall survival will be measured from the date of inclusion to the date of death from any cause.
Patients who are alive at the time of analysis will be censored at the date of the last contact.
|
Up to 3.5 years
|
COMPLETE RESPONSE RATE
Time Frame: 30 or 32 weeks (depending on induction cycle length)
|
Assessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 2007)). Patient without response assessment (due to whatever reason) will be considered as nonresponder. |
30 or 32 weeks (depending on induction cycle length)
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Fritz OFFNER, MD, Lymphoma Study Association
- Study Chair: Corinne HAIOUN, PhD, Lymphoma Study Association
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Antibiotics, Antineoplastic
- Gemcitabine
- Oxaliplatin
- Rituximab
- Inotuzumab Ozogamicin
Other Study ID Numbers
- CMC-R-GEMOX
- 2011-003849-18 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B-Cell Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on Rituximab, CMC544, Gemcitabine and Oxaliplatine
-
The Lymphoma Academic Research OrganisationInnate PharmaRecruitingPeripheral T Cell Lymphoma | Relapse/RecurrenceFrance, Spain, Belgium, Germany
-
Assistance Publique - Hôpitaux de ParisTerminated
-
Centre Hospitalier Universitaire de BesanconTerminatedMetastatic Pancreatic AdenocarcinomaFrance
-
German Low Grade Lymphoma Study GroupTerminatedIndolent LymphomaGermany
-
Fudan UniversityCompleted
-
Zhejiang Cancer HospitalRecruitingDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma RefractoryChina
-
Sun Yat-sen UniversityCompletedLymphoma, Large B-Cell, DiffuseChina
-
SanofiCompletedNon Small Cell Lung CancerFrance
-
CTI BioPharmaCompletedDiffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 LymphomaUnited States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma